triflusal has been researched along with salicylates in 137 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 23 (16.79) | 18.7374 |
1990's | 25 (18.25) | 18.2507 |
2000's | 55 (40.15) | 29.6817 |
2010's | 31 (22.63) | 24.3611 |
2020's | 3 (2.19) | 2.80 |
Authors | Studies |
---|---|
Garcia Rafanell, J; Planas, JM; Puig-Parellada, P | 1 |
Bellés, L; Forn, J; García Rafanell, J | 1 |
Conte, L; Forn, J; Mis, R; Ramis, J | 2 |
de la Cruz, JP; Mata, JM; Sanchez de la Cuesta, F | 1 |
Campos, A; Cervós-Navarro, J; Heye, N; Kannuki, S | 1 |
Conget, JI; Esmatjes, E; Fernandez, MR; Ferrer, JP; Gaya, J; Rivera, F; Vilardell, E | 1 |
Barbanoj, MJ; Conte, L; Forn, J; Jané, J; Mis, R; Ramis, J; Torrent, J | 1 |
Alvarez, L; Castillo-Olivares, JL; de Haro, J; Escudero, MC; Millán, I; Rodríguez, V | 1 |
Altimiras, J; Arís, A; Augé, JM; Bassons, T; Bonal, J; Caralps, JM; Castellarnau, C; Crexells, C; Guiteras, P; Masotti, M | 1 |
Conget, I; Coves, MJ; Esmatjes, E; Gállego, M; Maseras, M | 1 |
Alvarez, L; Castillo-Olivares, JL; del Moral, JH; Escudero-Vela, MC; Millán, I; Rodríguez, V | 1 |
De la Cruz, JP; Garcia-Arnes, J; Pavia, J; Sanchez de la Cuesta, F | 1 |
Forn, J; García-Rafanell, J; Gomez, L; Ramis, J | 1 |
Forn, J; García Rafanell, J; Gómez, L | 1 |
Albors, M; De Castellarnau, C; Rutllant, ML; Sancho, MJ; Vila, L | 1 |
Coves, MJ; Esmatjes, E; Figuerola, D; Gallego, M; Maseras, M; Ríos, M | 1 |
Bellido, I; de la Cruz, JP; González, MC; Pavia, J; Sánchez de la Cuesta, F | 1 |
Bellido, I; de la Cruz, JP; Pavia, J; Sánchez de la Cuesta, F | 1 |
Aliaga, A; Planells, I; Serrano, G | 1 |
Dominguez, MJ; Forn, J; Iriarte, JA; Olabarría, I; Sáez, Y; Vacas, M; Velasco, A | 1 |
Forn, J; García Rafanell, J; Ramis, J; Sánchez, MS | 3 |
Azanza, JR; Honorato, J | 1 |
Forn, J; Rimbau, V; Torralba, A | 1 |
Fernández, A; Forn, J; López, R; Rimbau, V | 1 |
Forn, J; García Rafanell, J; Sánchez, MS | 1 |
Aranza Perea, J; Arcas, R; Herreros, J; Honorato, J; Rocha, E | 1 |
Bergqvist, D; Granero, X; Lafoz, E; Monreal, M; Olazabal, A; Roca, J; Salazar, X; Soler, J | 1 |
De La Cruz, JP; García, PJ; Sánchez de la Cuesta, F; Smith-Agreda, JM; Villalobos, MA | 1 |
Cruz, JM; García-Rubira, JC; López, V; Navas, JC; Plaza, L | 1 |
Auteri, A; Di Perri, T; Franchi, M; Messa, GL | 1 |
Alegría, E; Artal, A; Cabadés, A; Cruz-Fernández, JM; López-Bescós, L; Malpartida, F; Martín-Jadraque, L; Plaza, L; Ruipérez, JA; Velasco, J | 1 |
Campos, A; Cervos-Navarro, J; Heye, N; Sampaolo, S | 1 |
Ambrosoli, L; Angaroni, A; Auteri, A; Borgatti, E; Catalano, M; De Vizzi, GB; Forconi, S; Fossati, L; Girardello, R; Poli, A | 1 |
Calpe Climent, AV; Horrach Pérez, M; Llobera C-anaves, J; Peña Díaz, JJ; Rodríguez Moreno, C; Thomàs Mulet, V; Tomàs Arbona, FJ | 1 |
Alvarez-Sabín, J; Martín, R; Matías-Guiu, J; Molina, C | 1 |
López-Pousa, S; Lozano-Gallego, M; Martí-Cuadros, AM; Mercadal-Dalmau, J; Vilalta-Franch, J | 1 |
Alvarez-Sabín, J; Codina, A; Matías-Guiu, J | 1 |
Bellver, T; Casado, S; Esteban, A; Farré, J; García-Durán, M; Guerra, JI; López-Farré, A; Mata, P; Montón, M; Rico, LA; Romero, J; Sánchez de Miguel, L; Sierra, MP | 1 |
Goa, KL; McNeely, W | 1 |
Arjona, A; Bartolomé, MT; Millán, I; Zabala, JA | 1 |
Alvarez Sabín, J; Codina Puiggrós, A; Galiano, L; Matías-Guiu, J | 1 |
Alonso, A; Bayón, Y; Cavalcanti, F; Fernández de Arriba, A; Forn, J; García-Rafanell, J; Merlos, M; Miralles, A | 1 |
Alonso, A; Bayón, Y; Sánchez Crespo, M | 1 |
Lee, AY; Lee, KH; Yoo, SH | 1 |
Ambrosoli, L; Belcaro, G; Cesarone, MR; DeSanctis, MT; Fugazza, L; Girardello, R; Incandela, L; Laurora, G; Peracino, L; Poli, A | 1 |
Bayés de Luna, A | 1 |
Cabadés, A; Castro-Beiras, A; Cruz-Fernández, JM; García-Dorado, D; López García-Aranda, V; López-Bescós, L; Marfil, F; Martín-Jadraque, L; Navarro, E; Torres, F; Velasco, JA | 1 |
Ayala, R; Bellver, T; Casado, S; Farré, J; García-Durán, M; Gómez, J; González-Fernández, F; Guerra, JI; Jiménez, A; López-Farré, A; Mar Arriero, M; Marcos, P; Montón, M; Núñez, A; Rico, L; Romero, J; Sánchez de Miguel, L | 1 |
De La Cruz, JP; Del Prado, MF; Prieto, MA; Sánchez de la Cuesta, F | 1 |
Segade Buceta, XM | 1 |
Acarin, L; Castellano, B; González, B | 3 |
Casado, S; De Miguel, LS; Del Mar Arriero, M; Farré, AL; Farré, J; García-Cañete, J; Gómez, J; Jiménez, A; Montón, M; Núñez, A; Rico, L; Rodríguez-Feo, JA | 1 |
Aliaga, A; Nagore, E; Pérez-Ferriols, A; Sánchez-Motilla, JM; Serrano, G | 1 |
Berdié, J; Galindo, G; Morató, J; Navarro, MA; Peiró, R; Plana, A | 1 |
Crespo, MS; de Arriba, AF; Fuentes, L; Hernández, M; Merlos, M; Nieto, ML | 1 |
Boscá, F; Cuquerella, MC; Marín, ML; Miranda, MA | 1 |
Darbà, J; Izquierdo, I; Navas, C; Pontes, C; Rovira, J | 1 |
Apostolou, D; Comelli, S; Maselli, M; Moniaci, D; Ortensio, M; Scovazzi, P; Varetto, G; Zan, S | 1 |
Companion, J; Escriba, A; Guillén, M; Lourenzo, PI; Perez Gomez, F; Perez Saldaña, D; S-Harguindey, L; Vargas, E | 1 |
Alvarez-Sabín, J; Ferro, JM; Jiménez, MD; Lago, A; Matías-Guiu, J; Melo, T; Torres, F | 1 |
Tong, DC | 1 |
Cho, HY; Jeong, TJ; Lee, YB | 1 |
Garcia-Porrua, C; Gonzalez-Gay, MA; Gonzalez-Juanatey, C; Testa, A | 1 |
Del Valle, C; Ferrit, M; López, M; Luque, R; Martínez, F | 1 |
Anderson, DC; Goldstein, LB | 1 |
Abiusi, G; Bauso-Tosselli, L; Culebras, A; Domínguez, R; Famulari, A; Ferrari, J; Gori, H; Reich, E; Rey, R; Rotta-Escalante, R; Vila, J | 1 |
Arrebola, MM; De La Cruz, JP; González-Correa, JA; Guerrero, A; Muñoz-Marín, J; Ruiz-Villafranca, D; Sánchez De La Cuesta, F; Ureña, IM | 2 |
García Robaina, JC; Sánchez-Machín, I; Torre Morin, F | 1 |
Aguilar, MR; Fernández, M; Gallardo, A; Rodríguez, G; San Román, J | 1 |
Alegría, E; Berjón, J; Iriarte, JA; Mataix, L; Pérez-Gómez, F; Salvador, A; Zumalde, J | 1 |
Falk, RH | 1 |
Barbanoj, MJ; Brunner, M; Donner, A; Eichler, HG; Herranz, U; Izquierdo, I; Klein, N; Müller, M; Valle, M | 1 |
Borja, J | 1 |
Weinberger, J | 1 |
Aramendi, JI; Campos, V; Martinez-León, J; Mestres, CA; Muñoz, G; Navas, C | 1 |
Alvarez-Sabin, J; Costa, J; Ferro, JM; Matias-Guiu, J; Torres, F | 1 |
Cechetto, DF; Cheng, G; Hachinski, V; Whitehead, S | 1 |
Ezekowitz, MD; Jamieson, DG; Parekh, A | 1 |
Avellone, G; Ballone, E; Ciabattoni, G; Davì, G; Di Febbo, C; Di Nicola, M; Falco, A; Pinto, A; Salvati, F; Vitacolonna, E | 1 |
de Arriba, AF; Laguna, JC; Merlos, M; Planavila, A; Rodríguez-Calvo, R; Sánchez, RM; Vazquez-Carrera, M | 1 |
Murdoch, D; Plosker, GL | 1 |
Borja, J; García, O; Izquierdo, I | 1 |
Bereznicki, LR; Jackson, SL; Jeffrey, EC; Peterson, GM | 1 |
De La Cruz, JP; González-Correa, JA | 1 |
Allen, GV; Bayona, NA; Cechetto, DF; Cheng, G; Hachinski, VC; Whitehead, SN | 1 |
del Valle, C; Ferrit, M; Martínez, F | 1 |
Borja, J; Fraj, J; Izquierdo, I; Pérez, I; Picado, C; Valero, A; Vives, R | 1 |
Argemí, A; Domingo, C; López-Periago, A; Saurina, J | 1 |
Arnaiz, E; Bassols, J; Casamitjana, R; Fernández-Real, JM; Gomis, R; López-Bermejo, A; Nadal, A; Pérez, I; Piquer, S; Ricart, W; Ropero, AB | 1 |
Badimon, L; Duran, X; Sánchez, S; Vilahur, G | 1 |
Azanza, JR; Campanero, MA; Escolar, M; Quetglas, EG; Sádaba, B | 1 |
González, B; Montero Domínguez, M; Zimmer, J | 1 |
Blanca, M; Jiménez, MC; Lhiaubet-Vallet, V; Miranda, MA; Montanaro, S | 1 |
Arumugam, S; Boey, FY; Huang, Y; Mohanty, M; Umashankar, PR; Venkatraman, SS | 1 |
Alvarez-Sabín, J; García-Bonilla, L; Krupinski, J; Montaner, J; Penalba, A; Quintana, M | 1 |
Asenjo, S; Bover, R; Coleto, D; Fernández, C; Igea, A; Maluenda, MP; Pérez-Gómez, F; Pérez-Saldaña, R; Suárez, M | 1 |
Kang, HJ; Kim, HS; Kim, SY; Kim, YS; Koo, BK; Park, JS; Suh, JW | 1 |
Agulló, J; Bacskai, BJ; Borrelli, LA; Clarimón, J; Coma, M; Da Rocha-Souto, B; España, J; Garcia-Alloza, M; Gómez-Isla, T; Guardia-Laguarta, C; Hyman, BT; Lleó, A; Rodríguez, M; Sánchez, MB; Saura, CA; Scotton, TC; Serenó, L | 1 |
Borja, J; Cebrecos, J; García-Rafanell, J; Izquierdo, I; Pelagio, P; Rovira, S; Torres, F | 1 |
Arumugam, S; Boey, FY; Huang, Y; Khanolkar, L; Lahti, EM; Mohanty, M; Umashankar, PR; Vaishnav, S; Venkatraman, SS | 1 |
Frautschy, SA | 1 |
Enache, TA; Fatibello-Filho, O; Oliveira-Brett, AM | 1 |
Buján, J; Duocastella, L; Fernández-Gutiérrez, M; Honduvilla, NG; López-Bravo, A; Molina, M; Parra, J; Rodríguez, G; San Román, J | 1 |
Balduini, W; Cechetto, DF; Cheng, G; Cimino, M; Hachinski, VC; Massoni, E; Whitehead, SN | 1 |
Antonijoan, RM; Azaro, A; Balanzó, J; Barbanoj, MJ; Blanch, I; Borja, J; Donado, E; Gich, I; Izquierdo, I; Sainz, S | 1 |
Borja, J; García-Rafanell, J | 1 |
Baek, IH; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, J; Seo, JJ; Seong, SJ; Yoon, YR; Yun, HY | 1 |
Alarcón-Galván, G; Cámara-Lemarroy, CR; Cordero-Pérez, P; Fernández-Garza, NE; Guzmán-de la Garza, FJ; Muñoz-Espinosa, LE; Torres-Gonzalez, L | 1 |
Acciarresi, M; Caso, V; Paciaroni, M; Pezzella, FR; Santalucia, P | 1 |
García, E; Guarinos, J; Ioannidis, K; Larman, M; Moreu, J; Ortas, MR; Piqué, N; Puigfel, B; Rincón, A; Rumoroso, JR; Serra, A; Zueco, JJ | 1 |
Hua, W; Huang, M; Wang, M; Zhang, Q; Zhou, W; Zong, S | 1 |
Alvarez-Sabín, J; Maisterra, O; Quintana, M; Santamarina, E | 1 |
Kang, W; Kwon, KI; Lee, BY; Park, S; Yeul Ma, J; Yoon, YR; Yun, HY | 1 |
Blasco, A; Del Pozo, MD; Escudero, R; Gonzalez, I; Lobera, T; Sánchez, M | 1 |
Gwon, MR; Han, S; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, JG; Park, SM; Seong, SJ; Yang, DH; Yoon, YR | 1 |
Ding, LK; Ding, Y; Ge, J; Jia, YY; Lu, CT; Song, W; Song, Y; Wen, AD; Yang, J | 1 |
Chang, HJ; Cho, IJ; Chung, N; Hong, GR; Jang, Y; Kim, KJ; Rah, YM; Shin, S | 1 |
Domingo, C; Salerno, A; Saurina, J | 1 |
Espasandín-Arias, M; García-Rodiño, S; Rodríguez-Granados, MT; Vázquez-Osorio, I | 1 |
Ahn, SH; Han, SW; Kim, YJ; Kim, YN; Lee, KY; Oh, SH; Seo, WK; Yu, S | 1 |
Cubells Sánchez, L; Martínez Leboráns, L; Pérez Ferriols, A; Zaragoza Ninet, V | 1 |
Choi, KJ; Kim, SW; Lee, JK; Park, JY; Yoon, SH | 1 |
Colás, C; Cubero, JL; Millán, P; Simó Sánchez, B | 1 |
Fuertes Ferre, G; Galache Osuna, JG; Laita Monreal, S; Ortas Nadal, MDR; Sánchez Insa, E; Sánchez Rubio-Lezcano, J | 1 |
Amtul, Z; Cechetto, DF; Haque, W | 1 |
Adamopoulos, D; Asimakopoulos, C; Bourdakis, A; Chantzichristos, VG; Darmanis, P; Dimitriadou, A; Gkiokas, S; Goudevenos, JA; Ipeirotis, K; Kalantzi, KI; Kitikidou, K; Klonaris, I; Kostaki, A; Logothetis, D; Mainas, K; Mais, T; Maragiannis, A; Martiadou, K; Mavronasos, K; Michelongonas, I; Mitropoulos, D; Ntalas, IV; Panagiotakos, DB; Papadimitriou, G; Papadopoulos, A; Papaioakeim, M; Sofillas, K; Stabola, S; Stefanakis, E; Stergiou, D; Thoma, M; Tselepis, AD; Tsoumani, ME; Zenetos, A; Zisekas, S | 1 |
de Abajo, FJ; García-Rodríguez, LA; Gil, M; Montoya, H; Rodríguez-Martín, S; Rodríguez-Miguel, A | 1 |
Doherty, P; Duty, S; Fletcher, EJR; Jamieson, AD; Williams, G | 1 |
Barrutia, L; Garabito Solovera, E; Garayar Cantero, M; Ruiz-Sanchez, D; Santamarina Albertos, A; Valtueña, J; Volo, V | 1 |
Berenguer, A; de la Torre Hernandez, JM; Diaz, JF; Garcia Del Blanco, B; Gomez-Lara, J; Gomez-Menchero, A; Moreno, R; Muñoz-Garcia, E; Otaegui, I; Rondan, J; Rumoroso, JR; Sainz-Laso, F; Subinas, A; Zueco, J | 1 |
Alonso-Ventura, V; Andrés Esteban, EM; Casasnovas Lenguas, JA; Cubero Saldaña, JL; Diarte de Miguel, JA; Fuertes Ferre, G; Galache Osuna, JG; Jimeno Sánchez, J; Linares Vicente, JA; Ortas Nadal, MDR; Pérez Guerrero, A | 1 |
8 review(s) available for triflusal and salicylates
Article | Year |
---|---|
Triflusal.
Topics: Adult; Angina Pectoris; Animals; Aspirin; Carotid Stenosis; Humans; In Vitro Techniques; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Pulmonary Embolism; Randomized Controlled Trials as Topic; Salicylates; Thrombophlebitis | 1998 |
[The risk of hemorrhage in long-term use of aspirin and triflusal].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebral Infarction; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Salicylates; Sex Factors; Time Factors | 1998 |
Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Salicylates; Stroke; Ticlopidine; Warfarin | 2005 |
Triflusal for preventing serious vascular events in people at high risk.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Salicylates; Stroke | 2005 |
Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Recurrence; Salicylates; Stroke; Ticlopidine | 2005 |
Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Cerebral Infarction; Drug Interactions; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Salicylates; Thromboembolism | 2006 |
Triflusal: an antiplatelet drug with a neuroprotective effect?
Topics: Animals; Biological Availability; Clinical Trials as Topic; Female; Humans; Male; Neuroprotective Agents; Platelet Aggregation Inhibitors; Salicylates; Stroke; Tissue Distribution | 2006 |
Antiplatelet treatment in primary and secondary stroke prevention in women.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; Naphthalenes; Platelet Aggregation Inhibitors; Primary Prevention; Propionates; Salicylates; Secondary Prevention; Sex Factors; Stroke; Ticlopidine | 2012 |
37 trial(s) available for triflusal and salicylates
Article | Year |
---|---|
Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Compliance; Prospective Studies; Random Allocation; Salicylates; Vascular Patency | 1989 |
Effect of treatment with an inhibitor of platelet aggregation on the evolution of background retinopathy: 2 years of follow-up.
Topics: Adult; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Female; Humans; Male; Platelet Aggregation Inhibitors; Salicylates; Visual Acuity | 1989 |
Platelet count, antiplatelet therapy and pulmonary embolism--a prospective study in patients with hip surgery.
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hip Fractures; Hip Prosthesis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Postoperative Complications; Prospective Studies; Pulmonary Embolism; Radionuclide Imaging; Salicylates; Thrombophlebitis; Treatment Outcome; Ultrasonography; Vomiting | 1995 |
Outcome of patients with diabetes and unstable angina. A subgroup analysis in the Spanish Multicentre Trial of trifusal in unstable angina. Grupo de Estudio del Trifusal en la Angina Inestable.
Topics: Aged; Angina, Unstable; Diabetes Complications; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prognosis; Salicylates; Spain; Treatment Outcome | 1994 |
Action of 2-acetoxy-trifluoromethylbenzoic acid (Triflusal) on platelet function after repeated oral administration in man: a pharmacological clinical study.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; beta-Thromboglobulin; Blood Platelet Disorders; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Factor 3; Platelet Factor 4; Salicylates; Thromboxane B2 | 1993 |
Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial. Grupo de Estudio del Triflusal en la Angina Inestable.
Topics: Administration, Oral; Aged; Angina, Unstable; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Salicylates; Spain; Survival Rate | 1993 |
Triflusal in the treatment of patients with chronic peripheral arteriopathy: multicentre double-blind clinical study vs placebo.
Topics: Adult; Aged; Chronic Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Salicylates | 1995 |
[Triflusal in the prevention of vascular dementia].
Topics: Aged; Cerebrovascular Disorders; Dementia, Vascular; Female; Humans; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Salicylates | 1997 |
[Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease].
Topics: Adult; Aspirin; Brain Ischemia; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Salicylates; Survival Rate | 1997 |
Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Chi-Square Distribution; Disease Progression; Double-Blind Method; Female; Femoral Artery; Humans; Male; Middle Aged; Pilot Projects; Placebos; Platelet Aggregation Inhibitors; Salicylates; Stomach; Tunica Intima; Tunica Media; Ultrasonography | 1999 |
Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Salicylates; Spain; Treatment Outcome | 2000 |
Influence of triflusal on platelet activation after coronary artery bypass graft.
Topics: Adenosine Diphosphate; Adult; Aged; beta-Thromboglobulin; Collagen; Coronary Artery Bypass; Erythrocyte Count; Female; Hematocrit; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Myocardial Ischemia; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Salicylates; Thromboxane B2; Time Factors | 2000 |
A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: role in platelet function.
Topics: Administration, Oral; Adult; Humans; Male; Neutrophils; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Salicylates | 2000 |
Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction.
Topics: Acute Disease; Aspirin; Double-Blind Method; Drug Costs; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Salicylates; Spain | 2002 |
Platelet aggregation in different antithrombotic regimens. Possible proaggregant effect of low level oral anticoagulation.
Topics: Acenocoumarol; Adenosine Diphosphate; Aged; Analysis of Variance; Anticoagulants; Arachidonic Acid; Atrial Fibrillation; Blood Platelets; Collagen; Embolism; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Salicylates; Time Factors | 2002 |
Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
Topics: Aspirin; Cardiovascular Diseases; Cerebral Infarction; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Salicylates; Secondary Prevention; Stroke; Survival Analysis | 2003 |
Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study.
Topics: Aged; Aspirin; Cerebral Infarction; Double-Blind Method; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Odds Ratio; Pilot Projects; Platelet Aggregation Inhibitors; Salicylates; Secondary Prevention; Stroke; Survival Analysis; Treatment Outcome | 2004 |
Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
Topics: Acenocoumarol; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dose-Response Relationship, Drug; Drug Therapy, Combination; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; International Normalized Ratio; Intracranial Embolism; Male; Middle Aged; Mitral Valve Stenosis; Platelet Aggregation Inhibitors; Proportional Hazards Models; Salicylates; Survival Analysis; Treatment Outcome | 2004 |
Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers.
Topics: Adult; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Female; Humans; Male; Metabolic Clearance Rate; Models, Biological; Neuroprotective Agents; Salicylates | 2005 |
Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial.
Topics: Acenocoumarol; Aged; Anticoagulants; Bioprosthesis; Epidemiologic Methods; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Hemorrhage; Salicylates; Thromboembolism | 2005 |
Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.
Topics: Adult; Aged; Aspirin; Biomarkers; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Radioimmunoassay; Retrospective Studies; Salicylates; Thromboxane B2; von Willebrand Factor | 2005 |
Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Probability; Reference Values; Respiratory Function Tests; Risk Assessment; Salicylates; Severity of Illness Index; Single-Blind Method; Treatment Outcome | 2008 |
Salicylates increase insulin secretion in healthy obese subjects.
Topics: Aged; C-Reactive Protein; Calcium; Cross-Over Studies; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Salicylates | 2008 |
Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Platelet Aggregation Inhibitors; Reference Standards; Salicylates; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Therapeutic Equivalency | 2008 |
Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Biomarkers; Brain Ischemia; Female; Humans; Inflammation Mediators; Logistic Models; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Salicylates; Stroke; Time Factors; Treatment Outcome | 2009 |
Comparison of triple antiplatelet therapy including triflusal and conventional dual therapy in patients who underwent drug-eluting stent implantation.
Topics: Drug Combinations; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Penile Implantation; Platelet Aggregation Inhibitors; Prospective Studies; Salicylates | 2009 |
Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study.
Topics: Adult; Area Under Curve; Biological Availability; Capsules; Chemistry, Pharmaceutical; Cross-Over Studies; Double-Blind Method; Female; Half-Life; Humans; Male; Pharmaceutical Solutions; Platelet Aggregation Inhibitors; Salicylates; Young Adult | 2010 |
Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study.
Topics: Administration, Oral; Adult; Capsules; Double-Blind Method; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Gastrointestinal Tract; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Salicylates; Spain; Statistics as Topic; Therapeutic Equivalency; Young Adult | 2011 |
A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.
Topics: Administration, Oral; Adult; Arachidonic Acid; Asian People; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cross-Over Studies; Dose-Response Relationship, Drug; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Salicylates; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult | 2011 |
Long-term clinical performance of paclitaxel-eluting stents coated with a bioactive polymer (P-5) containing a triflusal derivative: results of the REWAC registry.
Topics: Aged; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Incidence; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Polymers; Prospective Studies; Registries; Salicylates; Thrombosis; Treatment Outcome | 2013 |
Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects.
Topics: Adult; Area Under Curve; Asian People; Female; Healthy Volunteers; Humans; Male; Salicylates; Young Adult | 2014 |
Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Topics: Aged; Aspirin; Brain Ischemia; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Intracranial Arteriosclerosis; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Recurrence; Salicylates; Secondary Prevention; Vascular Diseases | 2014 |
Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study.
Topics: Adult; Cross-Over Studies; Healthy Volunteers; Humans; Male; Middle Aged; Models, Theoretical; Platelet Aggregation Inhibitors; Republic of Korea; Salicylates; Young Adult | 2014 |
Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Biotransformation; Capsules; China; Cross-Over Studies; Dietary Fats; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Platelet Aggregation Inhibitors; Postprandial Period; Salicylates; Therapeutic Equivalency; Young Adult | 2015 |
Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Female; Humans; Indocyanine Green; Male; Middle Aged; Perfusion Imaging; Platelet Aggregation Inhibitors; Recurrence; Salicylates; Treatment Outcome | 2015 |
Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Topics: Brain Ischemia; Cerebral Hemorrhage; Chemoprevention; Clopidogrel; Cytochrome P-450 CYP2C19; Follow-Up Studies; Genotype; Humans; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Recurrence; Salicylates; Secondary Prevention; Single-Blind Method; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Greece; Hemorrhage; Humans; Intracranial Embolism; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Salicylates; Secondary Prevention; Stroke; Time Factors; Treatment Outcome | 2019 |
92 other study(ies) available for triflusal and salicylates
Article | Year |
---|---|
Comparison of the inhibitory effects of acetylsalicylic acid and trifusal on enzymes related to thrombosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aspirin; Cattle; Cyclooxygenase Inhibitors; Fibrinolytic Agents; Horses; In Vitro Techniques; Microsomes; Myocardial Contraction; Oxidoreductases; Salicylates; Sheep; Thrombosis; Thromboxane-A Synthase | 1979 |
[Induction of pulmonary thrombosis in mice, rabbits and hamsters by intravenous injection of arachidonic acid. Comparative study of 3 experimental models in vivo and the antithrombotic activity of triflusal].
Topics: Animals; Arachidonic Acids; Cricetinae; Disease Models, Animal; Fibrinolytic Agents; Injections, Intravenous; Lung Diseases; Mice; Rabbits; Respiration Disorders; Salicylates; Thrombosis | 1979 |
In-vitro protein binding interaction between a metabolite of triflusal, 2-hydroxy-4-trifluoromethylbenzoic acid and other drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Protein Binding; Salicylates; Serum Albumin | 1992 |
Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man.
Topics: Administration, Oral; Animals; Blood Proteins; Female; Humans; Orosomucoid; Platelet Aggregation Inhibitors; Protein Binding; Rats; Rats, Inbred Strains; Salicylates; Serum Albumin | 1992 |
Triflusal vs aspirin on the inhibition of human platelet and vascular cyclooxygenase.
Topics: 6-Ketoprostaglandin F1 alpha; Arachidonic Acid; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Humans; In Vitro Techniques; Mesenteric Arteries; Muscle, Smooth, Vascular; Platelet Aggregation Inhibitors; Salicylates; Thromboxane B2 | 1992 |
Effects of triflusal and acetylsalicylic acid on microthrombi formation in experimental brain ischemia.
Topics: Animals; Aspirin; Brain Ischemia; Cerebral Arteries; Intracranial Embolism and Thrombosis; Male; Platelet Aggregation Inhibitors; Rats; Rats, Inbred Strains; Salicylates | 1991 |
Effects of thromboxane synthesis inhibitor triflusal on renal hemodynamics in microalbuminuric diabetic patients.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 1; Dinoprostone; Female; Glomerular Filtration Rate; Humans; Male; Platelet Aggregation Inhibitors; Renal Circulation; Renin; Salicylates; Thromboxane B2 | 1990 |
Pharmacokinetics of triflusal after single and repeated doses in man.
Topics: Adult; Chromatography, High Pressure Liquid; Half-Life; Humans; Male; Platelet Aggregation Inhibitors; Random Allocation; Salicylates | 1990 |
[Use of aspirin in the primary prevention of vascular thrombi. A comparative study with other anti-aggregant drugs].
Topics: Animals; Aspirin; Dipyridamole; Dogs; Drug Evaluation; Drug Therapy, Combination; Platelet Aggregation Inhibitors; Salicylates; Thrombosis | 1989 |
Prevention of the formation of arterial thrombi using different antiplatelet drugs: experimental study in dogs.
Topics: Animals; Aspirin; Dipyridamole; Dogs; Indium Radioisotopes; Platelet Aggregation Inhibitors; Salicylates; Scintillation Counting; Thrombosis | 1989 |
Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients.
Topics: Adult; Aspirin; beta-Thromboglobulin; Diabetes Mellitus, Type 1; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandins F; Salicylates; Thromboxane B2 | 1988 |
Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets.
Topics: Alprostadil; Animals; Aspirin; Blood Platelets; Cyclic AMP; Dipyridamole; Drug Interactions; In Vitro Techniques; Male; Rats; Rats, Inbred Strains; Salicylates; Salicylic Acid | 1986 |
Protective effect of triflusal and acetylsalicylic acid against arachidonic acid induced cerebrovascular occlusion in anesthetized rats.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Cerebrovascular Disorders; Electroencephalography; Male; Platelet Aggregation; Rats; Rats, Inbred Strains; Salicylates | 1987 |
Effects and interaction studies of triflusal and other salicylic derivatives on cyclooxygenase in rats.
Topics: Alprostadil; Animals; Aorta, Thoracic; Aspirin; Blood Platelets; Drug Interactions; In Vitro Techniques; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred Strains; Salicylates; Salicylic Acid; Vasodilator Agents | 1988 |
[Effect of platelet antiaggregant treatment on the evolution of simple diabetic retinopathy. Preliminary results].
Topics: Adolescent; Adult; Diabetic Retinopathy; Drug Evaluation; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Salicylates | 1988 |
Platelet antiaggregatory effect of triflusal in human whole blood.
Topics: Adenosine Diphosphate; Adult; Collagen; Epinephrine; Humans; In Vitro Techniques; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Salicylates; Thromboxane B2 | 1988 |
Effect of triflusal and acetylsalicylic acid on platelet aggregation in human whole blood: influence of red blood cells and leukocytes.
Topics: Adult; Aspirin; Erythrocytes; Humans; In Vitro Techniques; Leukocytes; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Salicylates; Salicylic Acid | 1988 |
Photosensitivity associated with triflusal (Disgren).
Topics: Female; Humans; Middle Aged; Photosensitivity Disorders; Salicylates | 1987 |
Effects of triflusal in patients with prosthetic heart valves.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Female; Heart Valve Prosthesis; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Count; Salicylates | 1985 |
[Effect of chronic administration of triflusal on pulmonary thrombosis induced by arachidonic acid].
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Female; Fibrinolytic Agents; Male; Rats; Rats, Inbred Strains; Salicylates; Thrombosis | 1982 |
[Inhibition of platelet cyclo-oxygenase by triflusal].
Topics: Animals; Blood Platelets; Cyclooxygenase Inhibitors; Female; Humans; In Vitro Techniques; Male; Rats; Rats, Inbred Strains; Salicylates | 1982 |
[Triflusal].
Topics: Humans; Platelet Aggregation; Salicylates; Thromboembolism; Vascular Diseases | 1982 |
[Induction of pulmonary thrombosis in the rat by i.v. injections of ADP and the antithrombotic activity of triflusal].
Topics: Adenosine Diphosphate; Animals; Female; Fibrinolytic Agents; Injections, Intravenous; Lung Diseases; Male; Rats; Rats, Inbred Strains; Salicylates; Thrombosis | 1982 |
[Distribution and metabolism of triflusal].
Topics: Animals; Male; Rats; Rats, Inbred Strains; Salicylates; Tissue Distribution | 1982 |
[Pharmacokinetic study of triflusal (UR-1501)].
Topics: Administration, Oral; Animals; Dogs; Injections, Intravenous; Kinetics; Salicylates | 1981 |
[Comparative study of the in vitro anti-aggregating action of various salicylic derivatives].
Topics: Animals; Aspirin; Chemical Phenomena; Chemistry; Organophosphates; Platelet Aggregation; Rats; Salicylates | 1981 |
[Clinico-biological effectiveness of triflusal during the postoperative period of patients with chronic ischemic syndrome of the extremities].
Topics: Adult; Aged; Blood Vessel Prosthesis; Drug Evaluation; Endarterectomy; Female; Fibrinolytic Agents; Humans; Ischemia; Leg; Male; Middle Aged; Postoperative Complications; Salicylates; Thrombosis | 1981 |
Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers.
Topics: Adult; Animals; Aspirin; Blood Platelets; Endothelium, Vascular; Humans; Male; Perfusion; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabbits; Salicylates | 1995 |
Morphometrical evaluation of triflusal in brain infarction.
Topics: Animals; Brain; Brain Damage, Chronic; Capillaries; Cerebral Infarction; Dose-Response Relationship, Drug; Intracranial Embolism and Thrombosis; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Salicylates | 1993 |
[Prescription of platelet antiaggregants in secondary prevention of ischemic heart disease].
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Dipyridamole; Drug Prescriptions; Family Practice; Female; Humans; Male; Medical Audit; Medicine; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prevalence; Primary Health Care; Salicylates; Spain; Specialization; Ticlopidine; Urban Population | 1996 |
[The tolerance of two therapeutic uses of triflusal in patients with ischemic stroke. Letter].
Topics: Brain Ischemia; Cerebral Hemorrhage; Female; Humans; Male; Platelet Aggregation Inhibitors; Salicylates | 1996 |
Comparison of in vitro effects of triflusal and acetysalicylic acid on nitric oxide synthesis by human neutrophils.
Topics: Aspirin; Cyclic GMP; Cyclooxygenase Inhibitors; Humans; Neutrophils; Nitric Oxide; Platelet Aggregation Inhibitors; Salicylates | 1998 |
[Intracerebral hemorrhage and treatment with platelet aggregation inhibitors: study of 21 cases].
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; Risk Factors; Salicylates | 1998 |
Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Inflammation; Isoenzymes; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Membrane Proteins; NF-kappa B; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred Lew; Salicylates | 1999 |
4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation.
Topics: Animals; Aspirin; Cell Line; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Macrophages, Peritoneal; NF-kappa B; Nitric Oxide; Platelet Aggregation Inhibitors; Rats; RNA, Messenger; Salicylates; Thrombin; Tumor Necrosis Factor-alpha; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 1999 |
A case of photoallergic drug eruption caused by triflusal (Disgren).
Topics: Aged; Cerebrovascular Disorders; Drug Eruptions; Humans; Male; Platelet Aggregation Inhibitors; Salicylates; Skin Tests | 1999 |
May aspirin be replaced in the treatment of myocardial infarction?
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Salicylates | 2000 |
[The effect of triflusal on human platelet aggregation and secretion: the role of nitric oxide].
Topics: Adult; Blood Platelets; Citrulline; Cyclic GMP; Guanosine Monophosphate; Humans; Neutrophils; Nitric Oxide; Platelet Aggregation; Platelet Aggregation Inhibitors; Salicylates; Transforming Growth Factor beta | 2000 |
[Impact of various objectives related to the rational use of medication in a primary care area].
Topics: Antihypertensive Agents; Costs and Cost Analysis; Drug Prescriptions; Drug Utilization; Humans; Platelet Aggregation Inhibitors; Primary Health Care; Quinolones; Retirement; Salicylates; Spain; Urban Population | 2000 |
Oral administration of the anti-inflammatory substance triflusal results in the downregulation of constitutive transcription factor NF-kappaB in the postnatal rat brain.
Topics: Administration, Oral; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Brain Chemistry; Immunohistochemistry; Neuroglia; Neurons; NF-kappa B; Rats; Rats, Long-Evans; Salicylates | 2000 |
Photosensitivity associated with treatment with triflusal.
Topics: Aged; Aged, 80 and over; Female; Humans; Ischemic Attack, Transient; Photosensitivity Disorders; Platelet Aggregation Inhibitors; Salicylates | 2000 |
[Prevention of thromboembolic disease in patients with heart disease].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cross-Sectional Studies; Dipyridamole; Female; Heart Diseases; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Salicylates; Sex Factors; Thromboembolism; Ticlopidine | 2000 |
Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells.
Topics: Astrocytoma; Blotting, Western; Brain Neoplasms; Cyclooxygenase 2; DNA, Complementary; Electrophoresis; Humans; Indicators and Reagents; Isoenzymes; Membrane Proteins; Neoplasm Proteins; Neurons; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Reverse Transcriptase Polymerase Chain Reaction; Salicylates; Tumor Cells, Cultured; Vascular Cell Adhesion Molecule-1 | 2001 |
Photochemistry of 2-hydroxy-4-trifluoromethylbenzoic acid, major metabolite of the photosensitizing platelet antiaggregant drug triflusal.
Topics: Dermatitis, Photoallergic; Photochemistry; Platelet Aggregation Inhibitors; Protein Binding; Salicylates; Serum Albumin, Bovine; Spectrometry, Fluorescence | 2001 |
Triflusal posttreatment inhibits glial nuclear factor-kappaB, downregulates the glial response, and is neuroprotective in an excitotoxic injury model in postnatal brain.
Topics: Administration, Oral; Animals; Astrocytes; Brain; DNA-Binding Proteins; Down-Regulation; Drug Administration Schedule; Glial Fibrillary Acidic Protein; Microglia; Microinjections; N-Methylaspartate; Neuroglia; Neuroprotective Agents; NF-kappa B; Platelet Aggregation Inhibitors; Rats; Rats, Long-Evans; Salicylates; STAT3 Transcription Factor; Trans-Activators | 2001 |
Compliance of geriatric patients subjected to antiplatelet agents with Triflusal in peripheral arteriopathy. Preliminary data.
Topics: Age Factors; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Female; Follow-Up Studies; Humans; Male; Patient Compliance; Platelet Aggregation Inhibitors; Risk Factors; Salicylates; Time Factors | 2002 |
Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal after postnatal excitotoxic damage.
Topics: Administration, Oral; Animals; Astrocytes; Cyclooxygenase 2; Disease Models, Animal; Inflammation Mediators; Interleukin-1; Isoenzymes; Microglia; Microinjections; N-Methylaspartate; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Neurotoxins; Neutrophil Infiltration; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Long-Evans; Salicylates; Somatosensory Cortex; Tumor Necrosis Factor-alpha | 2002 |
Can aspirin ever be surpassed for stroke prevention?
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Fibrinolytic Agents; Forecasting; Humans; Platelet Aggregation Inhibitors; Salicylates; Stroke | 2003 |
Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography.
Topics: Animals; Area Under Curve; Chromatography, High Pressure Liquid; Humans; Male; Rats; Reproducibility of Results; Salicylates; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2003 |
Potential role of mitral valve strands on stroke recurrence in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Echocardiography, Transesophageal; Female; Humans; Middle Aged; Mitral Valve; Mitral Valve Prolapse; Platelet Aggregation Inhibitors; Recurrence; Salicylates; Stroke; Treatment Outcome | 2003 |
The stability of 2-acetoxy-4-trifluoromethylbenzoic acid (Triflusal) in micellar pseudophase.
Topics: Algorithms; Alkalies; Bromides; Chemical Phenomena; Chemistry, Physical; Drug Stability; Electric Conductivity; Hydrolysis; Indicators and Reagents; Kinetics; Micelles; Platelet Aggregation Inhibitors; Potassium Compounds; Salicylates; Surface-Active Agents; Temperature | 2004 |
Aspirin: it's hard to beat.
Topics: Aspirin; Cerebral Infarction; Humans; Pilot Projects; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Salicylates; Stroke; Treatment Outcome | 2004 |
Effects of triflusal on oxidative stress, prostaglandin production and nitric oxide pathway in a model of anoxia-reoxygenation in rat brain slices.
Topics: Analysis of Variance; Animals; Aspirin; Disease Models, Animal; Dose-Response Relationship, Drug; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Hypoxia; In Vitro Techniques; L-Lactate Dehydrogenase; Lipid Peroxidation; Male; Nitrates; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxidative Stress; Oxygen; Platelet Aggregation Inhibitors; Prostaglandins; Rats; Rats, Wistar; Salicylates | 2004 |
Widespread eczema from triflusal confirmed by patch testing.
Topics: Diabetes Mellitus, Type 2; Diagnosis, Differential; Drug Eruptions; Eczema; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Patch Tests; Platelet Aggregation Inhibitors; Salicylates | 2004 |
Polymeric drugs with prolonged sustained delivery of specific anti-aggregant agents for platelets: kinetic analysis of the release mechanism.
Topics: Acrylamides; Biocompatible Materials; Blood Platelets; Drug Design; Free Radicals; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Magnetic Resonance Spectroscopy; Models, Chemical; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymers; Salicylates; Thrombin; Time Factors; Toluene; Water | 2004 |
Reconsidering combined antiplatelet and anticoagulant therapy in atrial fibrillation.
Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; International Normalized Ratio; Male; Middle Aged; Mitral Valve Stenosis; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Salicylates; Warfarin | 2004 |
Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids.
Topics: Animals; Aspirin; Brain Chemistry; Dinoprostone; Glutathione; Hypoxia, Brain; In Vitro Techniques; L-Lactate Dehydrogenase; Lipid Peroxidation; Male; Nerve Tissue Proteins; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Reperfusion Injury; Salicylates; Thiobarbituric Acid Reactive Substances | 2005 |
Oral antiplatelet therapy.
Topics: Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Salicylates; Ticlopidine | 2005 |
Interaction between a rat model of cerebral ischemia and beta-amyloid toxicity: II. Effects of triflusal.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Astrocytes; Behavior, Animal; Brain; Brain Ischemia; Corpus Striatum; Cytokines; Disease Models, Animal; Endothelins; Glial Fibrillary Acidic Protein; Hippocampus; Immunohistochemistry; Inflammation; Microglia; Neurons; Peptides; Rats; Rats, Wistar; Salicylates; Temperature | 2005 |
Inhibition of cardiac hypertrophy by triflusal (4-trifluoromethyl derivative of salicylate) and its active metabolite.
Topics: Animals; Aspirin; Base Sequence; Cardiomegaly; DNA Primers; Electrophoretic Mobility Shift Assay; Immunoprecipitation; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; RNA Processing, Post-Transcriptional; Salicylates; Signal Transduction | 2006 |
Antithrombotic treatment in atrial fibrillation. Response to: Bereznicki LR, Peterson GM, Jackson SL, Jeffrey EC: the risks of warfarin use in the elderly. Expert Opin. Drug Saf. (2006) 5(3):417-431.
Topics: Acenocoumarol; Aged; Anticoagulants; Atrial Fibrillation; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Salicylates; Thromboembolism; Treatment Outcome; Warfarin | 2006 |
Antithrombotic treatment in atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Death, Sudden, Cardiac; Geriatrics; Humans; Platelet Aggregation Inhibitors; Salicylates | 2006 |
Effects of triflusal and aspirin in a rat model of cerebral ischemia.
Topics: Animals; Aspirin; Brain Ischemia; Disease Models, Animal; Drug Therapy, Combination; Male; Rats; Rats, Wistar; Salicylates | 2007 |
The study of the influence of surfactant charge on alkaline hydrolysis reactions of acetylsalicylic acid (ASA) and triflusal (TFL) using spectrophotometric methods.
Topics: Algorithms; Alkalies; Aspirin; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Platelet Aggregation Inhibitors; Polyethylene Glycols; Quaternary Ammonium Compounds; Salicylates; Salicylic Acid; Sodium Dodecyl Sulfate; Sodium Hydroxide; Spectrophotometry, Ultraviolet; Static Electricity; Surface-Active Agents; Water | 2007 |
Spectroscopic and chromatographic characterization of triflusal delivery systems prepared by using supercritical impregnation technologies.
Topics: Chromatography, Supercritical Fluid; Delayed-Action Preparations; Hydrogen-Ion Concentration; Salicylates; Solubility; Spectrophotometry; Technology, Pharmaceutical | 2008 |
Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2.
Topics: Animals; Aspirin; Base Sequence; Blood Vessels; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; DNA Primers; Endothelium, Vascular; Fibrinolytic Agents; In Vitro Techniques; Male; Perfusion; Rabbits; Recurrence; RNA, Messenger; Salicylates; Thrombosis | 2008 |
Neuroprotective effects of the anti-inflammatory compound triflusal on ischemia-like neurodegeneration in mouse hippocampal slice cultures occur independent of microglia.
Topics: Analysis of Variance; Animals; Animals, Newborn; Cell Count; Cell Death; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Glucose; Hippocampus; Ischemia; Mice; Mice, Inbred C57BL; Microglia; Nerve Degeneration; Neurons; Neuroprotective Agents; NF-kappa B; Plant Lectins; Propidium; Salicylates; Tissue Culture Techniques | 2009 |
Photonucleophilic addition of the epsilon-amino group of lysine to a triflusal metabolite as a mechanistic key to photoallergy mediated by the parent drug.
Topics: Binding Sites; Dermatitis, Photoallergic; Humans; Lysine; Photolysis; Protein Binding; Salicylates; Serum Albumin; Spectrometry, Fluorescence | 2009 |
The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model.
Topics: Animals; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Chromium Alloys; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Drug Therapy, Combination; Drug-Eluting Stents; Immunosuppressive Agents; Platelet Aggregation Inhibitors; Prosthesis Design; Salicylates; Sirolimus; Swine; Thrombosis; Treatment Outcome | 2009 |
Long-term follow-up of atrial fibrillation patients in the NASPEAF study. Prospective evaluation of different antiplatelet treatments.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Male; Platelet Aggregation Inhibitors; Prospective Studies; Salicylates; Time Factors | 2009 |
Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Axons; Brain; Brain-Derived Neurotrophic Factor; Central Nervous System Agents; Cognition Disorders; Cytokines; Disease Models, Animal; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neuroglia; Plaque, Amyloid; Proto-Oncogene Proteins c-fos; Salicylates | 2010 |
In vitro and in vivo performance of a dual drug-eluting stent (DDES).
Topics: Animals; Antibiotics, Antineoplastic; Coated Materials, Biocompatible; Drug Delivery Systems; Drug-Eluting Stents; Humans; Hyperplasia; Materials Testing; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Salicylates; Sirolimus; Surface Properties; Swine; Thrombosis | 2010 |
Thinking outside the box about COX-1 in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Central Nervous System Agents; Cognition Disorders; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Humans; Membrane Proteins; Mice; Salicylates | 2010 |
Electrochemical behavior of triflusal, aspirin and their metabolites at glassy carbon and boron doped diamond electrodes.
Topics: Alkalies; Aspirin; Boron; Carbon; Diamond; Electrochemistry; Electrodes; Glass; High-Throughput Screening Assays; Hydrogen-Ion Concentration; Hydrolysis; Molecular Structure; Particle Size; Salicylates; Salicylic Acid; Surface Properties; Water | 2010 |
Bioactive polymeric systems with platelet antiaggregating activity for the coating of vascular devices.
Topics: Acrylic Resins; Blood Platelets; Blood Vessel Prosthesis; Cell Adhesion; Cell Line; Cell Survival; Coated Materials, Biocompatible; Endothelial Cells; Humans; Microscopy, Electron, Scanning; Platelet Aggregation; Platelet Aggregation Inhibitors; Salicylates; Surface Properties | 2010 |
Triflusal reduces cerebral ischemia induced inflammation in a combined mouse model of Alzheimer's disease and stroke.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antigens, CD; Brain Ischemia; Disease Models, Animal; Endothelin-1; Humans; Inflammation; Mice; Mice, Inbred C57BL; Mice, Transgenic; NF-kappa B; Platelet Aggregation Inhibitors; Salicylates; Stroke; tau Proteins; Tumor Necrosis Factor-alpha | 2010 |
Letter by Borja and Garcia-Rafanell regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association"
Topics: Aspirin; Carotid Arteries; Clinical Trials as Topic; Endarterectomy, Carotid; Guidelines as Topic; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Salicylates; Stents; Stroke | 2011 |
Comparative effects of triflusal, S-adenosylmethionine, and dextromethorphan over intestinal ischemia/reperfusion injury.
Topics: Animals; Antioxidants; Dextromethorphan; Intestines; Male; Malondialdehyde; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Reperfusion Injury; S-Adenosylmethionine; Salicylates; Tumor Necrosis Factor-alpha | 2011 |
Semi-mechanistic modelling and simulation of inhibition of platelet aggregation by antiplatelet agents.
Topics: Adult; Blood Platelets; Cilostazol; Clopidogrel; Half-Life; Humans; Models, Theoretical; Platelet Aggregation; Platelet Aggregation Inhibitors; Retrospective Studies; Salicylates; Tetrazoles; Ticlopidine; Young Adult | 2014 |
Tolerance of triflusal in patients with immediate cutaneous hypersensitivity to nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Drug Hypersensitivity; Drug Tolerance; Female; Humans; Hypersensitivity, Immediate; Male; Middle Aged; Platelet Aggregation Inhibitors; Salicylates; Skin Diseases | 2014 |
Supercritical CO2 foamed polycaprolactone scaffolds for controlled delivery of 5-fluorouracil, nicotinamide and triflusal.
Topics: Carbon Dioxide; Drug Delivery Systems; Fluorouracil; HeLa Cells; Humans; Niacinamide; Polyesters; Salicylates; Tissue Scaffolds | 2015 |
Photosensitivity associated with systemic triflusal therapy.
Topics: Aged; Humans; Male; Photosensitivity Disorders; Salicylates; Thromboembolism; Urticaria | 2016 |
Atypical photosensitivity associated with triflusal.
Topics: Aged, 80 and over; Facial Dermatoses; Humans; Male; Photosensitivity Disorders; Platelet Aggregation Inhibitors; Salicylates; Skin Tests | 2016 |
Neuroprotective effect of triflusal and its main metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), in the postischemic brain.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Brain; Brain Ischemia; Cytokines; Infarction, Middle Cerebral Artery; Male; Neurons; Neuroprotective Agents; Rats, Sprague-Dawley; Salicylates | 2017 |
Aspirin desensitization in patients with coronary artery disease: Cost savings.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost Savings; Desensitization, Immunologic; Drug Hypersensitivity; Drug Substitution; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Salicylates; Ticlopidine | 2017 |
Triflusal in Patients With Aspirin Hypersensitivity Treated With Coronary Stent Implantation.
Topics: Aged; Aspirin; Drug Hypersensitivity; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Male; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Salicylates; Stents | 2018 |
Dipyridamole plus Triflusal versus Triflusal Alone in Infarct Reduction after Middle Cerebral Artery Occlusion.
Topics: Animals; Brain; Cytoprotection; Dipyridamole; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; Rats, Wistar; Salicylates | 2018 |
Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Colorectal Neoplasms; Dual Anti-Platelet Therapy; Female; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Protective Factors; Risk Reduction Behavior; Salicylates; Spain | 2019 |
Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats.
Topics: Albuterol; Animals; Brain; Computer Simulation; Corpus Striatum; Dimethadione; Dopaminergic Neurons; Drug Repositioning; Female; Fibroblast Growth Factors; Humans; MCF-7 Cells; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Salicylates; Substantia Nigra; Trazodone; Treatment Outcome | 2019 |
Photosensitivity to Triflusal.
Topics: Humans; Photosensitivity Disorders; Salicylates | 2021 |
First-in-Man Evaluation of a Sirolimus-Eluting Stent With Abluminal Fluoropolymeric/Triflusal Coating With Ultrathin Struts by OCT at 9 Months' Follow-Up: The PROMETHEUS Study.
Topics: Coronary Vessels; Drug-Eluting Stents; Humans; Neointima; Percutaneous Coronary Intervention; Prospective Studies; Salicylates; Sirolimus; Stents; Tomography, Optical Coherence; Treatment Outcome | 2021 |
Triflusal in Patients with Acute Coronary Syndrome and Acetylsalicylic Acid Hypersensitivity.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Salicylates; Treatment Outcome | 2021 |